Spruce Biosciences, Inc.

General Information

We are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. We are initially developing our wholly owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia, or CAH. Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. In a 12-week Phase 2a proof-of-concept clinical trial, tildacerfont-treated patients suffering from classic CAH who had poor disease control despite being on standard of care therapy achieved approximately 80% reductions in hormones that are key indicators of poor disease control. Furthermore, 163 subjects across six clinical trials to date have been administered tildacerfont with no drug-related serious adverse events, or SAEs, reported.

Industry: Pharmaceuticals
Employees: 15
Founded: 2014
Contact Information
Address 2001 Junipero Serra Boulevard, Suite 640, Daly City, California 94014
Phone Number (415) 294-1687
Web Address https://www.sprucebiosciences.com/
View Prospectus: Spruce Biosciences, Inc.
Financial Information
Market Cap $318.9mil
Revenues $0 mil (last 12 months)
Net Income $-17.4 mil (last 12 months)
IPO Profile
Symbol SPRB
Exchange NASDAQ
Shares (millions): 6.0
Price range $15.00 - $15.00
Est. $ Volume $90.0 mil
Manager / Joint Managers Cowen and Company/ SVB Leerink/ Credit Suisse/ RBC Capital Markets
Expected To Trade: 10/9/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change